Achondroplasia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Achondroplasia Market Outlook
Thelansis’s “Achondroplasia Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Achondroplasia treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Achondroplasia
Overview
Achondroplasia
is an autosomal-dominant disorder caused by mutations in the type 3 receptor
for a fibroblast growth factor (FGFR3). A range of distinctive physical
features characterizes it. Achondroplasia can be suspected during pregnancy in
the third trimester when abnormal ultrasound findings, such as limb
foreshortening (in the 95th percentile) and a low nasal bridge, become evident.
These findings may prompt further intra-uterine imaging. After birth,
individuals with achondroplasia display clinical characteristics, including
short limbs, especially in the proximal segment, a long trunk, and a narrow
thorax. Generally, their birth height is within the normal range. These
individuals typically have a large head with frontal bossing, potentially
leading to obstetric complications during childbirth. The midface tends to be
hypoplastic, indicating an endochondral growth defect at the skull’s base. The
hands and fingers of individuals with achondroplasia are notably short. In
early life, they exhibit a trident appearance due to an inability to fully
oppose the third and fourth digits. This condition also features shortened long
bones with wide metaphyses, a slim, radiolucent area in the proximal femur, and
a horizontal acetabular roof in antenatal radiographic images.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment